Michael A. Horberg, MD, MAS, FACP, AAHIVS

Michael A. Horberg, MD, MAS, FACP, AAHIVS Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

(510) 891-3779 (phone)
michael.horberg@kp.org

Michael A. Horberg, MD, MAS, FACP, AAHIVS, is a research scientist at the Kaiser Permanente Northern California Division of Research and a clinical instructor at Stanford University Medical School. He is a graduate of the Boston University College of Liberal Arts and Medical School and the University of California, San Francisco (master’s of advanced studies in clinical research). Dr. Horberg is a fellow of the American College of Physicians. Dr. Horberg’s primary research interests are related to HIV and other sexually transmitted diseases, including syphilis and gonorrhea. He serves on the board of directors of the HIV Medicine Association of the Infectious Disease Society of America and as director of HIV/AIDS nationally for Kaiser Permanente and The Permanente Federation. Dr. Horberg co-chairs the AMA/NCQA/HRSA/IDSA/CMS Expert Panel on HIV-related provider performance measures, and he chairs the Central Research Committee for Kaiser Permanente Northern California. In that capacity, he also serves on the Kaiser Permanente Northern California Health Services Institutional Review Board. Dr. Horberg is past-president of the national Gay and Lesbian Medical Association.

Current Position(s):

Research Scientist I, Division of Research, Kaiser Permanente Northern California
Director, HIV/AIDS, Kaiser Permanente and The Permanente Federation
Co-chair, AMA/HRSA/NCQA/IDSA Physician Consortium for Performance Improvement, HIV/AIDS Expert Panel
Clinical Lead, HIV/AIDS, Care Management Institute
Chair, Central Research Committee, The Permanente Medical Group, Inc
Chair, KPNC HIV Provider and Therapeutics Subcommittee
Conference Chair, Kaiser Permanente National HIV/AIDS, Hepatitis and STD Conference
Chair, KPNC-KPSC Interregional HIV Clinical Guidelines Committee
Member, Board of Directors, HIV Medical Association/Infectious Disease Society of America
Local Research Chair, Kaiser Permanente Santa Clara
Physician Specialist in HIV Disease, Kaiser Permanente Santa Clara
Physician Specialist in Eating Disorders, Kaiser Permanente Santa Clara
Member, KPNC Health Services Institutional Review Board
Senior Physician, The Permanente Medical Group, Inc, Santa Clara, CA, HIV and Internal Medicine

Primary Research Interests:

Health service outcomes for HIV-infected patients, including HIV quality care metrics
Medication adherence issues in these patients, with special emphasis on evaluating multi-disciplinary HIV care and its impact on medication adherence and clinical outcomes and resource utilization
The epidemiology of HIV disease
Long-term effects of medications used to treat HIV disease, cost of HIV care and changes with time, and HIV quality care metrics
Other sexually transmitted diseases, including syphilis and gonorrhea

Observational Post-Authorization Study of Patients Treated With Raltegravir

The purpose of this study is to assess the phase IV safety of raltegravir, an integrase inhibitor recently released for use as an HIV antiretroviral medication, in the course of ordinary clinical practice in Kaiser Permanente Northern and Southern California.
Funder: Merck and Co., Inc.
Principal Investigator: Horberg, Michael

Impact of Missed Office Visits on HIV Outcomes and Mortality

This study will investigate if the frequency of missed visits during the first year after new HIV diagnosis predicts HIV-related outcomes after that year, as has been seen in public care settings.
Funder: Kaiser Permanente Community Benefit Program
Principal Investigator: Horberg, Michael

Optimizing Multidisciplinary HIV Care Team for Maximal HAART Adherence

Optimizing Multidisciplinary HIV Care Team for Maximal HAART Adherence
Funder: Kaiser Foundation Research Institute
Principal Investigator: Horberg, Michael

Optimizing Multidisciplinary HIV Care Team for Max

Retrospective cohort study to determine optimized HIV multidisciplinary care team to maximize HAART adherence and other HIV outcomes and minimize urgent care utilization.
Funder: National Institute of Mental Health
Principal Investigator: Horberg, Michael

Gilead Modern Haart

This retrospective cohort study, using data from Kaiser Permanente, determines the predictors of initiating HAART therapy in the modern treatment era and has that changed over time.
Funder: Gilead, Inc.
Principal Investigator: Horberg, Michael

Considerations of Emerging Issues in the Treatment of HIV ("CEITH")

This interregional study investigates the epidemiology of advanced treatment failure among HIV-infected patients, the utilization of a new class of antiretroviral medications, and the impact of low level viremia on HIV-infected patients being treated with antiretorivral therapy.
Funder: Merck and Co., Inc.
Principal Investigator: Horberg, Michael

North America AIDS Cohorts Collaboration on Research and Disease (NA-ACCORD)

This study's intent is to perform HIV-related analyses that cannot be accomplished with limited power of individual cohorts or could not be reasonably accomplished by clinical trials. These analyses will be achieved by combining collaborative HIV cohort data (including Kaiser Permanente Northern California) to achieve appropriate power and analyses that could simulate randomized trials where appropriate.
Funder: Nat. Inst. of Allergy and Infectious Diseases
Principal Investigator: Horberg, Michael

Economic Implications of Care of HIV-Positive Patients With Multi-drug Resistance Within a Managed Care Population

This retrospective study uses cost and other data from Kaiser Permanente to determine the added overall cost of patients who are on their third (or likely greater) HAART regimen compared to antiretroviral naive patients beginning their first regimen in the modern HIV treatment era.
Funder: Abbott
Principal Investigator: Horberg, Michael

United States Post-Licensure Safety (ISENTRESS™)

Five-year surveillance data study to assess safety of new antiretroviral medication raltegravir, with comparisons to rates among similar HIV-infected patients taking antiretroviral medications other than raltegravir.
Funder: Merck and Co., Inc.
Principal Investigator: Horberg, Michael

Treatment Regimen, Provider, and Clinical Characteristics Associated with Receipt of HAART: An Analysis from Kaiser Permanente

This retrospective cohort study, using Kaiser Permanente data, determines the predictors of initiating HAART therapy in the modern treatment era and if they have changed over time.
Funder: Gilead, Inc.
Principal Investigator: Horberg, Michael

Effect of Tenofovir on Renal Function--An Observational Cohort Study

This study seeks to determine the incidence of change in renal function of patients taking Tenofovir (TDF) and compare that to patients on other NRTI.
Funder: Gilead, Inc.
Principal Investigator: Horberg, Michael

Retrospective Review of Atazanavir Experience in Kaiser Permanente

This study will investigate the Kaiser Permanente experience with Atazanavir (ATV) to see what the success has been with a HAART regimen employing ATV.
Funder: Bristol-Myers Squibb
Principal Investigator: Horberg, Michael

Epidemiology and Clinical Outcome of HIV/HCV Co-Infection

This study uses the administrative databases within the Department of Veterans Affairs and Kaiser Permanente Health Care systems to determine the number of human immunodeficiency virus (HIV) infected patients, number of HIV/Hepatitis C virus (HCV) co-infected patients, their demographic and clinical characteristics, and co-morbid conditions that affect survival.
Funder: GMF
Principal Investigator: Horberg, Michael

Kaiser Permanente Division of Research